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INTRODUCTION
The importance of cardiovascular risk
management in general practice is
increasing.1,2 However, although many
patients without target organ damage will
benefit from treatment of hypertension
and/or hypercholesterolaemia, the therapy
is costly and side effects are common.3–5 To
improve the cost–benefit ratio, several
consecutive (inter)national guidelines have
been developed. Previously, the
Netherlands had separate guidelines for
hypertension and hypercholesterolaemia
until, in 2006, the interdisciplinary guideline
Cardiovascular Risk Management was
launched,6 which marked a change from
thinking in terms of individual risk factors
(disease management) into thinking in
terms of absolute risk (risk management).
The recommendations in this guideline are
based on the integrated SCORE function,
which includes age, sex, smoking
behaviour, systolic blood pressure, and
high-density lipoprotein (HDL)-cholesterol
to total cholesterol ratio.7 In cases of a
calculated 10-year risk of cardiovascular
mortality of 10% or more, treatment to
decrease systolic blood pressure to
140 mmHg or lower, and low-density
lipoprotein (LDL) cholesterol to 2.5 mmol/l
or lower is advised. Patients with a lower
risk may have insufficient benefit to warrant
medication. Consequently, numerous
patients per practice may be unnecessarily
treated based on the earlier (and now
obsolete) Dutch guidelines. Negative
consequences of this overprescribing
include the waste of resources (for example,
money and manpower), risk of adverse side
effects, and unnecessary medical usage.
When implementing the new Dutch
guideline in the authors’ general practices,
the question arose as to how many patients
receiving treatment for their ‘presumed’
cardiovascular risk had in fact now ‘lost’
their indication for medication based on the
new guideline and, if so, were they prepared
to stop medication. Although withdrawal of
medication from patients with well-
controlled blood pressure is reported to be
successful,8–10 these latter studies
concerned withdrawal of medication in
normotensive patients.
To the authors’ knowledge, there are no
studies with a broader scope with regard to
integrated cardiovascular risk
management. Therefore, this study
explored the feasibility and consequences of
a re-evaluation programme for patients
without target organ damage who were
treated for hypertension and/or
hypercholesterolaemia in general practices.
METHOD
Practices and patients
In six collaborating general practices with
10 GPs, in Katwijk (an urbanised rural town
in the Netherlands), serving a total of 17 200
patients (2500–3000 per practice), patients
were selected who had no known target
organ damage but were receiving
medication for hypertension and/or
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According to the new Dutch guideline for
cardiovascular risk management, patients with
a low risk of cardiovascular mortality may have
insufficient benefit to warrant medication.
Therefore, numerous patients per general
practice may be treated unnecessarily.
Aim
To explore the feasibility and consequences of a
re-evaluation programme for patients without
target organ damage who were treated for
hypertension and/or hypercholesterolaemia.
Design and setting
Practice-based intervention study in six general
practices.
Method
Patients treated for hypertension and/or
hypercholesterolaemia without target organ
damage (n = 833) were invited to re-evaluate
their cardiovascular risk and were advised
whether or not to stop medication. Patients
who discontinued medication were followed for
6 months. To determine indicators for
successful stopping, logistic regression
analyses were performed, and differences
between practices were analysed.
Results
About two-thirds of the patients were re-
evaluated and 61% of them had a low
calculated risk, especially younger patients,
females, and non-smokers. Of these, 42% were
advised to stop medication, especially younger
patients and non-smokers. Of those who
discontinued medication, 40% had restarted
within 6 months. After 6 months, 80 of the 833
patients (9.6%) had not restarted medication.
There were no important side effects related to
stopping medication.
Conclusion
Over 50% of patients without target organ
damage treated for hypertension and/or
hypercholesterolaemia may have insufficient
benefit to warrant medication. Younger patients,
females, and non-smokers in particular are
more likely to have an insufficient indication for
medication. GPs’ and nurse practitioners’ views
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hypercholesterolaemia. In the Netherlands,
all patients are registered at a general
practice, which also keeps the electronic
patient record with information on
diagnoses and medication.
From the electronic patient records, the
study selected all patients aged 25–75 years
who were prescribed drugs in the past
12 months with the following
cardiovascular-related Anatomical
Therapeutic Chemical (ATC) codes: C02
(antihypertensives), C03 (diuretics), C07
(beta-blocking agents), C08 (calcium-
channel blockers), C09 (agents acting on the
renin–angiotensin system), and C10 (lipid-
modifying agents).11 All patients who were
coded as being diagnosed with
cardiovascular disease were excluded, that
is, codes K74, K75, K76, K89, K90, K91, K92,
and T90, according to the International
Classification of Primary Care, version 1
(ICPC-1).12 The selected patients were then
manually screened and excluded in the case
of non-coded cardiovascular disease, or
when taking drugs for indications other than
hypertension or hypercholesterolaemia (for
example, for migraine). Patients on the final
list were invited by mail to re-evaluate their
risk of cardiovascular mortality and were
asked for written informed consent to
participate in the present study.
Re-evaluation
In the period January 2008 to November
2009 (23 months), patients were invited for a
re-evaluation by one of the nurse
practitioners at the general practice. At
intake the nurse practitioners registered
comorbidity (asthma/chronic obstructive
pulmonary disease [COPD], digestive tract,
urogenital tract, psychosocial, and/or
musculoskeletal problems), number of oral
drugs taken (0–2/>2), number of oral
cardiovascular drugs taken (0–2/>2),
prevalence of cardiovascular disease in
first-degree relatives (no/yes), and smoking
behaviour (no/yes).
The nurse practitioners then calculated
the patient’s risk of cardiovascular mortality
in the next 10 years, according to the new
Dutch guideline. For patients treated for
hypertension or hypercholesterolaemia, the
medical history was searched for the
pretreatment levels of either blood pressure
or cholesterol. If unknown, a systolic blood
pressure of 180 mmHg was assumed, and,
in the case of medical treatment for
hypercholesterolaemia, a HDL-cholesterol
to cholesterol ratio of 8.0 was assumed.
These levels were chosen because this
strategy would minimise the number of
underestimated levels (as a sort of worst-
case scenario). For patients aged between
66 and 75 years, the calculated risk for
patients aged 65 years was used, which is
the highest ranked age reported in the
guideline.
The new guideline advises medication in
cases of a high calculated risk: a 10-year
risk of cardiovascular mortality of 10% or
more or, in the case of an additional risk
factor (for example, obesity or family
history), of 5% or more. In cases of a lower
risk, patients were advised to visit their GP
to discuss continuation of medication. If
patients decided to stop medication, the GP
handed them a personalised medication-
reduction schedule which, in complicated
cases (such as polypharmacy), had been
discussed with a pharmacist (for example,
Box 1). Then, based on previous reports of
long-term diuretic medication,13 and a
relapse of high blood pressure in the case of
withdrawal,8–10,14 an individual follow-up took
place, which involved measuring blood
pressure, serum lipid levels, and possible
adverse events (for example, oedema,
headache, high blood pressure, high
cholesterol, feeling unwell, other problems).
In cases of stopping diuretics, follow-up
took place after 1, 2, 4, and 12 weeks, for
stopping other antihypertensive medication
after 4 and 12 weeks, and after stopping
only statins after 12 weeks.
For patients who decided to stop
medication, it was checked whether they
restarted cardiovascular drugs within
6 months and, for those who did, the most
important reason(s) for doing so were
registered. Whatever the decision, all
patients were offered a follow-up.
Registration and analysis
The outcome measures were: (1)
attendance for re-evaluation, (2) calculated
cardiovascular risk, (3) advice to stop
How this fits in
According to the new Dutch guideline for
cardiovascular risk management, patients
with a low risk of cardiovascular mortality
may have insufficient benefit to warrant
medication. In this study, the feasibility and
consequences of a re-evaluation
programme for patients without target
organ damage treated for hypertension
and/or hypercholesterolaemia in general
practice was explored. The results suggest
that stopping medication in patients with a
low risk for cardiovascular mortality is safe.
GPs’ and nurse practitioners’ views seem
to play a role in advising to stop or to
restart medication.
Box 1. Example of a
medication-reduction scheme
Patient Awith a calculated 3% risk of
cardiovascularmortality
Medication: hydrochlorthiazide 1 daily dose
25 mg, metoprolol 1 daily dose 50 mg
Reduction scheme:
• Week 1: hydroclorthiazide 1 daily dose 25 mg
and metoprolol 1 daily dose 25 mg
• Week 2: hydroclorthiazide 1 daily dose 25 mg
and metoprolol 1 daily dose 12.5 mg
• Week 3: follow-up control; hydroclorthiazide
1 daily dose 25 mg and metoprolol stop
• Week 4: hydroclorthiazide stop
• Weeks 5, 7, 9, and 16: follow-up control
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medication, (4) patients’ decision to stop
medication, and (5) patients’ compliance
with the discontinuation at 6 months.
To determine indicators for successful
stopping of medication, first, univariate
analyses were performed; Student’s t-test in
the case of a normal distribution and the
Wilcoxon test in other cases. In the
multivariate backward logistic regression
analyses, variables with P<0.20 in the
univariate analysis were included (P entry
0.05, P removal 0.10). To assess the
prognostic value of determinants, a
prognostic model was built by backward
stepwise logistic regression, and the area
under the receiver operating characteristic
curve (AUC) was calculated. In addition,
differences between practices were
analysed by one-way analysis of variance
and the Bonferroni post hoc test. Data
analysis was performed with the Statistical




After computerised selection of 980
patients, 147 met the exclusion criteria. Of
the remaining 833 invited patients, 562
(67%) were re-evaluated in a consultation
(Figure 1). There were no differences
between the re-evaluated and not re-
evaluated patients regarding sex and age,
although there were fewer smokers in the
re-evaluated group (20.5% versus 33.3%,
respectively). Attendance was similar in five
of the six practices (that is, 71–80%
attendance). One practice had a 46%
attendance, but also had no differences
regarding sex and age (Table 1).
Calculated cardiovascular risk
Over 60% of the re-evaluated patients had a
low 10-year risk of cardiovascular mortality
(Table 2). Being female, being younger, not
smoking, taking two or fewer different oral
drugs, and a lack of a family history of
cardiovascular disease were independent
predictors for having a low calculated risk of
cardiovascular mortality (Table 3). The AUC
of this model is 0.87. There were large
differences between the practices in the
calculated low risk (range 44–89%).
Advice to stopmedication
About 40% of the patients with a low risk of
cardiovascular mortality were advised to
stop cardiovascular medication. Non-
smokers and younger patients were more
often advised to stop medication. The AUC
of this model is 0.62. There were large
differences between practices in the
percentage of patients advised to stop
medication (range 19–80%).
Patients’ decision to stopmedication
Most patients who were advised to stop
medication decided to stop (135 of 144;
94%). Of those with a low calculated risk,
nearly 40% decided to stop (135 of 345). Of
all initially selected patients, 16% stopped
medication (135 of 833).
Of the patients who initially discontinued
their medication, 55 (41%) restarted their
medication within 6 months (most of them
within 3 months). The reasons for restarting
medication were headache (n = 12), ankle
oedema (n = 2), not feeling well (n = 9), and
high blood pressure and/or high cholesterol
(n = 32). However, of the latter 32 patients
with high blood pressure and/or high
cholesterol who restarted medication, in 21
patients the raised blood pressure and/or
cholesterol levels did not result in a risk of
cardiovascular mortality that was sufficiently
high enough to advise (the restart of)
Table 1. Data on included patients, attendance, low calculated
cardiovascular risk, and advice to stopmedication by practice
Advice to stop
Included Attendance, Low calculated risk medication,
Practice patients n (% of patients) n (% of attendance) n (% of low risk)
1 176 140 (79.5) 62 (44.3) 12 (19.4)
2 103 73 (70.9) 38 (52.1) 20 (52.6)
3 191 87 (45.5) 61 (70.1) 49 (80.3)
4 158 114 (72.2) 79 (69.3) 34 (43.0)
5 145 103 (71.0) 65 (63.1) 16 (24.6)
6 60 45 (75.0) 40 (88.9) 13 (32.5)
Total 833 562 (67.5) 345 (61.4) 144 (41.7)
Electronically selected




mortality (n = 345; 61%)
Advice to stop medication
(n = 144, 42%)
Patients who decided to stop
medication (n = 135; 94%)
Attendance (n = 562, 67%)
Patients who have still stopped 
medication after
6 months (n = 80; 59%)
Patients who decided not to
stop medication (n = 9; 6%)
High risk mortality on
cardiovascular mortality
(n = 217; 39%)
Non-attendance
(n = 271; 33%)
Advice not to stop medication
(n = 201; 58%)
Patients who have restarted
medication within 6 months
(n = 55; 41%)
Figure 1. Flow chart of the study patients.
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medication according to the new guideline.
Those who used more than two oral
drugs were more likely to restart medication
(Spearman’s rho –0.24; P = 0.005). No other
characteristics were associated with
restarting medication. After 6 months, 80
patients (9.6%) of the total 833 patients had
still discontinued their medication; these




According to the revised guideline, more
than half (61%) of the patients without target
organ damage who were treated for
hypertension and/or hypercholesterolaemia
may have had insufficient benefit to warrant
their medication. Overall, younger patients,
females, and non-smokers were more likely
to stop medication. Of those who initially
discontinued their medication, 40% had
restarted within 6 months; however, their
‘restart status’ often lacked an indication
related to high cardiovascular risk
according to the new guideline. After
6 months, 80 out of 833 (9.6%) patients
selected after applying exclusion criteria
had still discontinued their medication.
Strengths and limitations
To the authors’ knowledge, this is the first
study to explore the feasibility and
consequences of a re-evaluation
programme for patients without target
organ damage treated for hypertension
and/or hypercholesterolaemia in general
practice. The patients in the participating
practices were comparable to the general
Dutch population regarding the percentage
of patients treated for hypertension and/or
hypercholesterolaemia and the male to
female ratio of these patients.15–17 Therefore,
this study probably gives a representative
impression of the feasibility and
consequences of such a programme in
Dutch general practice and, perhaps, in
other countries with a comparable
healthcare system.
The follow-up period was only 6 months,
but because most patients who restarted
medication did so within 3 months, it can be
assumed that this 6-month period is
sufficient to provide a reliable insight.
There were differences between the
participating practices regarding
attendance, calculated risk, and advice to
stop medication (Table 1). This might be
caused, in part, by individual GPs and nurse
practitioners. For example, a GP and/or
nurse practitioner who is not totally
convinced about the advantage of stopping
medication may influence attendance and
subsequent advice to stop medication. The
differences between the practices regarding
the calculated risk may be due to the
threshold for prescribing medication in the
past. Patients from practices with a lower
tendency to prescribe medication in the past
are more likely to have a higher
cardiovascular risk at re-evaluation than
patients from practices with a higher
tendency in the past to prescribe.
Apart from the possible impact of the
GP/nurse practitioner, the patient’s
smoking behaviour may also play a role in
the advice to stop or continue medication.
This might be explained by the belief that
smokers, notwithstanding a low calculated
Table 2. Characteristics of the patients with a high risk and a low risk
>2 Oral Cardiovascular
Female, Age in years, Smokers, Comorbiditya, >2 Oral drugs, cardiovascular disease in
n (%) mean (SD) n (%) n (%) n (%) drugs, n (%) family, n (%)
High risk (n = 217) 105 (48.4) 64.5 (7.3) 55 (25.5) 113 (32.8) 142 (65.4) 32 (14.7) 123 (56.7)
Low risk (n = 345) 214 (62.0) 54.5 (8.5) 53 (15.4) 84 (38.7) 196 (56.8) 25 (7.2) 139 (40.3)
Advice to continue medication (n = 201) 122 (60.7) 55.4 (9.0) 38 (18.9) 74 (36.8) 112 (55.7) 14 (7.0) 81 (40.3)
Advice to stop medication (n = 144) 92 (63.9) 53.2 (7.7) 15 (10.4) 39 (27.1) 84 (58.3) 11 (7.6) 58 (40.3)
Still stopped after 6 months (n = 80) 50 (62.5) 51.8 (7.0) 6 (7.5) 23 (28.8) 21 (26.3) 1 (1.3) 33 (41.3)
Restarted within 6 months (n = 55) 36 (65.5) 53.9 (7.9) 8 (14.5) 13 (23.6) 16 (29.1) 7 (12.7) 23 (41.8)
Not stopped (n = 9) 6 (66.7) 58.7 (7.6) 1 (11.1) 3 (33.3) 4 (44.4) 3 (33.3) 2 (22.2)
SD = standard deviation. aAsthma/chronic obstructive pulmonary disease (COPD), digestive, urogenital, psychosomatic, and/or musculoskeletal problems.
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Table 3. Finalmodels for determinants of low cardiovascular risk
and subsequent advice to stopmedication:multivariate logistic
regression analysis; adjusted odds ratio (95% confidence interval)
Advice to stop
Low cardiovascular medication
risk (n = 562) (n = 345)
Female sex 4.4 (2.7 to 7.3) –a
Age (continuous variable) 0.8 (0.8 to 0.8) 1.0 (0.9 to 1.0)
Non-smokers 4.0 (2.2 to 7.2) 2.5 (1.3 to 5.0)
More than two different oral drugs 0.6 (0.4 to 1.0) –a
Negative family history of cardiovascular risk 4.3 (2.7 to 7.1) –a
aNot in final model.
risk, are, nevertheless, still at risk.
However, neither the influence of the
GP/nurse practitioner nor individual
smoking behaviour can sufficiently explain
the high percentage of patients (58%) who
were advised not to stop their medication in
the case of a low calculated risk.
Undoubtedly, other unexplored factors have
played a role.
After the electronic selection, manual
screening led to the exclusion of an
additional 147 patients (15%). The large
differences between practices show that
encoding medical problems according to
the ICPC codes had not been sufficiently
implemented in each practice.
Finally, by using the calculated risk for
patients aged 65 years for patients aged
66–75 years, the study may have
underestimated patients’ calculated risk.
However, this possible underestimation
may (at least) partially be compensated by
having assumed high pretreatment levels of
blood pressure and/or cholesterol, since
most of the missing data had to be imputed
in this older age group.
Comparison with existing literature
The study finding that it is feasible to stop
medication in hypertensive patients is in line
with other studies.9,10 In contrast to the
findings of Walma et al,13 only a few of the
patients in the present study restarted
medication because of oedema; most
restarted because of raised blood pressure.
In this study, about 40% of those who
initially stopped medication restarted it
within 6 months. This is similar to the
findings of Espeland et al, but lower than
the 55% restarting patients reported by
Aylett et al.9 Patients in the present study
who used more than two cardiovascular
drugs before stopping medication were
more likely to restart medication within
6 months, which is in line with the review
study of Nelson et al.14 However, these three
latter studies concerned withdrawal from
antihypertensive medication in
normotensive patients,9,13,14 whereas the
present study re-evaluated the need for
medication in both normotensive and
(presumed) hypertensive patients.
Although Kok et al calculated that
implementation of the new Dutch guideline
for cardiovascular risk management would
lead to a considerable increase in the
number of individuals requiring treatment,4
it is noteworthy that they did not include in
their calculation a possible re-evaluation of
patients with cardiovascular therapy. If they
had done so, the result of their calculation
would have been far more cost-effective.
Implications for practice and research
The present study shows that 10% of
patients treated for hypertension and/or
hypercholesterolaemia have still
discontinued medication after 6 months;
this is after having undergone re-evaluation,
being shown to have a low risk for
cardiovascular mortality, and being advised
and prepared to stop medication. In the
group of patients who initially stopped their
medication, no important adverse effects
(for example, heart failure or cardiovascular
events) were seen during follow-up;
therefore, it can be assumed that stopping
medication in this group is safe. Of course, it
is not known what the morbidity and
mortality will be in the discontinuing versus
the continuing group in the next 10 years.
However, as the new guidelines are based
on extensive clinical evidence, it can be
assumed that stopping superfluous
medication in patients with a low risk of
cardiovascular mortality will not, of itself,
increase this mortality rate. Based on these
results, the authors think that a re-
evaluation of the indication for
antihypertensive and/or cholesterol-
lowering therapy based on the revised
cardiovascular guideline is useful. To
improve efficiency, this re-evaluation
programme could, for example, be initially
focused only on non-smoking patients who
are younger than 60 years. This could lead to
22% of the invited patients (62 of 278
patients) eventually stopping their
medication. Further restriction to non-
smoking females aged ≤60 years leads to a
proportion of 25% (39 of 156 females).
However, in this latter case, 18 of the 833
patients, who otherwise would have been
invited to stop their medication, would be
‘missed’.
In addition, the views of the GPs, nurse
practitioners, and patients seem to play a
role in attendance and advising whether or
not to stop medication, and restarting
medication after withdrawal. Therefore, the
authors recommend further exploration of
these views on discontinuing preventive
cardiovascular medication, to enable better
information to be given to patients and to
overcome differences in the views of GPs
and nurse practitioners.
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